

Sabai Global Acquired by Thompson Street Capital Partners to Accelerate IBC and IRB Growth



Cell and gene therapies (C>) are one of the fastest-growing areas of therapeutics, contributing to some of the most significant disruptions in the pharmaceutical and biotech industries. In a fast-paced market expected to exceed \$42 billion by 2030, sponsors and CROs rely on specialized Institutional Biosafety Committees (IBCs) and Institutional Review Boards (IRBs) to address the unique biosafety challenges presented by C> clinical trials.

Sabai Global (Sabai) provides IBC, IRB, and related consulting services through its three operating subsidiaries: Clinical Biosafety Services (CBS); Castle IRB (Castle); and Shield Consulting (Shield). CBS provides accelerated, compliant review of gene transfer/gene therapy

clinical trials to a convened review of a site-specific Institutional Biosafety Committee (IBC). Castle offers IRB review services in many areas of research, including cell and gene therapy, and rare disease space. Shield provides expert consulting services on issues of biosafety, biorisk management and biosecurity. The combined value of these specialized services made Sabai the ideal target for a strategic growth investment from Thompson Street Capital Partners.

Crosstree's granular knowledge of the cell and gene therapy drug market helped Sabai evaluate both financial and strategic partners using real world data, not just hypotheses, and select the ideal partner to accelerate future growth.

Crosstree helps clients identify optimal transaction partners to accelerate growth and enhance value for all stakeholders.

ABOUT SABAI GLOBAL



Headquartered in Chesterfield, MO, Sabai Global is a clinical research safety firm specializing in custom solutions for biosafety and human research protections. The Company offers IBC and IRB review and comprehensive biosafety consulting services for sponsors, CROs, and institutions through its subsidiaries CBS IBC, Castle IRB, and Shield Consulting.

ABOUT TSCP

THOMPSON STREET
CAPITAL PARTNERS

Thompson Street Capital Partners is a St. Louis-based private equity firm focused on investing in founder-led middle market businesses. Sabai represents the firm's 88th investment in the Life Sciences & Healthcare sector since being founded in 2000

CROSSTREE'S EXPERTS ARE SPECIALISTS IN THE NUANCES OF HEALTH SCIENCE AND PROVIDE:

- Deep analytics of capabilities and gaps
- Systemized tactical strategies and a road map to success
- Engaged experts in market analysis, financials, and premium valuations
- Targeted and qualified prospects
- Up-to-date industry trend analysis and forecasting

All while prioritizing corporate core values.

MEETING THE NEEDS OF BOTH THE BUYER AND THE SELLER — BY THE NUMBERS AND BEYOND — IS CROSSTREE'S SPECIALTY.

Crosstree's [proven track record](#) of superior outcomes is the result of balanced, hands-on guidance from start to close. Partner with the leading health science experts today.



JASON LAYTON

Director

jason.layton@crosstreecapital.com

813-578-7109